TDC
SPPI

Thompson Davis & Co’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Thompson Davis & Co’s Portfolio SPPI Stock Details SPPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-125
Closed -$3K – 806
2018
Q2 		$3K Buy
+125
New +$2.32K 0.01% 591

Other funds holding SPPI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Thompson Davis & Co's SPPI Position: Q3 2018 in Review

Thompson Davis & Co sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q3 2018, closing a stake of 125 shares — an estimated $3K sold.

Thompson Davis & Co first reported a position in SPPI in Q2 2018 and held it in 1 quarter. The position peaked at $3K in Q2 2018. 190 funds tracked by Wall St. Rank hold SPPI as of Q3 2018.

  • Thompson Davis & Co reported no remaining Spectrum Pharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
  • Thompson Davis & Co sold 125 Spectrum Pharmaceuticals Inc shares in Q3 2018, an estimated $3K.
  • Thompson Davis & Co first reported a position in Spectrum Pharmaceuticals Inc in Q2 2018 and held it in 1 quarter.
  • Thompson Davis & Co's Spectrum Pharmaceuticals Inc position peaked at $3K in Q2 2018.
  • 190 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.